Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 22

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
 Statements of Comprehensive Income (unaudited) 

Three months endedJune 30,Six months endedJune 30,(in millions)2025202420252024Net earnings$941 $1,373 $2,230 $2,745 Foreign currency translation adjustments, net of tax expense (benefit) of $33 for the three months and $50 for the six months ended June 30, 2025 and $(4) for the three months and $(24) for the six months ended June 30, 20241,051 (157)1,538 (553)Net investment hedging activities, net of tax expense (benefit) of $(192) for the three months and $(269) for the six months ended June 30, 2025 and $23 for the three months and $80 for the six months ended June 30, 2024(698)84 (981)291 Pension and post-employment benefits, net of tax expense (benefit) of $— for the three months and $— for the six months ended June 30, 2025 and $3 for the three months and $4 for the six months ended June 30, 20244 8 2 18 Cash flow hedging activities, net of tax expense (benefit) of $(16) for the three months and $(20) for the six months ended June 30, 2025 and $(2) for the three months and $5 for the six months ended June 30, 2024(153)6 (172)36 Other comprehensive income (loss)204 (59)387 (208)Comprehensive income1,145 1,314 2,617 2,537 Comprehensive income attributable to noncontrolling interest3 3 6 6 Comprehensive income attributable to AbbVie Inc.$1,142 $1,311 $2,611 $2,531 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 2

AbbVie Inc. and Subsidiaries Condensed Consolidated Balance Sheets

(in millions, except share data)June 30,2025December 31, 2024(unaudited)AssetsCurrent assetsCash and equivalents$6,467 $5,524 Short-term investments— 31 Accounts rece